Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study

2015122 citationsJournal Articlebronze Open Access

Authors

This short-term study demonstrates the safety and feasibility of up to 246 million MPCs in subjects with type 2 diabetes.

Good health and well-being

Published in: Diabetes Care

Volume 38, Issue 9, pp. 1742-1749

Field-Weighted Citation Impact: 3.31